Meiji Seika Pharma Co.
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Meiji Seika Pharma Co. sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Meiji Seika Pharma Co.: 5 sponsored US clinical trials, none currently recruiting.
Meiji Seika Pharma Co. sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Onychomycosis, with 2 trials.
Upper-quartile sponsor footprint
Meiji Seika Pharma Co. sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia
NCT02459158
Efficacy and Safety Study of ME1111 in Patients With Onychomycosis
NCT02022215
Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers
NCT01961830
Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers
NCT01907776
Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients
NCT01841996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
Therapeutic Areas
How the Meiji Seika Pharma Co. early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: Onychomycosis (2 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Meiji Seika Pharma Co.: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Meiji Seika Pharma Co. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Meiji Seika Pharma Co. page
5 registered trials is a research-attention snapshot, not an endorsement of Meiji Seika Pharma Co. or any single study.
- None of Meiji Seika Pharma Co.'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Onychomycosis is the condition Meiji Seika Pharma Co. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Onychomycosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Meiji Seika Pharma Co. pipeline card: 5 registered trials from official public datasets.Report a data error.